International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationStereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials
Introduction
Pancreatic ductal adenocarcinoma is characterized by a poor prognosis, with a 5-year overall survival (OS) rate of about 6% (1). Surgery is the standard of care, with 5-year OS rates of 20% to 25%. The condition in most patients, however, is unresectable at the diagnosis, mainly because of locally advanced disease or distant metastases. In patients with locally advanced pancreatic cancer (LAPC), the integration of chemotherapy (CT) or chemoradiation treatment (CTRT) is a current therapeutic option but has been associated with a significant grade 3 to 4 toxicity rate and a median OS of 5 to 15 months (2).
In recent years, stereotactic body radiation therapy (SBRT) has been developed as a system for delivering a conformal high dose of radiation in 1 to 6 fractions to a tumor, with minimal dose to the surrounding critical tissue (3). This technique has been used in several sites, including the pancreas. The most significant advantage of SBRT compared with CTRT seems to be the short overall treatment delivery time, which avoids the need for prolonged systemic treatment breaks. Furthermore, focused irradiation might spare adjacent critical organs from acute and late toxicity. In contrast, the delivery of full or radiosensitizing doses of CT with SBRT has not been demonstrated to be safe and feasible compared with standard-dose CTRT, with which fluoropyrimidines are also usually prescribed. Concurrent CTRT might, therefore, improve both local control and systemic disease at the expense of increased in-field side effects and potentially delayed and complicated surgical treatment.
We investigated the role of SBRT in the treatment of unresectable pancreatic cancer (UPC) to confirm the hypothetical advantages of this innovative therapy compared with conventional CTRT. These possible advantages include greater local control related to the high doses used, the short overall treatment time, and, subsequently, optimal integration with systemic therapy (4).
To assess the efficacy of SBRT for patients with LAPC, we performed a systematic review and a pooled analysis of prospective trials or retrospective series exploring this type of locoregional treatment, with or without CT, in terms of OS (median OS and 1- to 2-year OS rates), locoregional control (LRC), progression-free survival (PFS), and toxicity.
Section snippets
Methods and Materials
The present meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (5).
Results
A total of 553 reports were retrieved from the electronic searches. After the removal of duplicates and screening by title, abstract, and full text, 19 full-text reports were included in the present meta-analysis 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 (Fig. 1, Table 1, Table 2). The treatment modalities included Cyberknife (8 studies), SBRT with a linear accelerator (6 studies), and different linear accelerator and Cyberknife techniques (4 studies). In 1
Discussion
The standard treatment of ULAPC, or initially BRPC, is challenging and differs to some extent. Surgical resection is the principal goal of neoadjuvant treatment of BRPC. Local disease control, OS improvement, and symptom palliation are the goals of ULAPC treatment. Despite the therapeutic progress of systemic and local treatment, ULAPC is associated with a dismal prognosis, similar to stage IV of the disease. Currently, the standard of care for patients who are unsuitable for surgery is the use
Conclusions
No evidence supports the claim that better outcomes result from SBRT compared with conventional RT. However, given the benefits of a shorter treatment time, the expected clinical advantage of dose escalation, and the increasing interest in SBRT in the oncologic field, our results provide meaningful aggregated information concerning the use of SBRT for patients with LAPC or BRPC.
References (47)
- et al.
Pancreatic cancer
Lancet
(2011) - et al.
American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy
Int J Radiat Oncol Biol Phys
(2010) - et al.
SBRT in pancreatic cancer: What is the therapeutic window?
Radiother Oncol
(2015) - et al.
Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy
Int J Radiat Oncol Biol Phys
(2008) - et al.
A challenge to traditional radiation oncology
Int J Radiat Oncol Biol Phys
(2004) - et al.
Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated
Int J Radiat Oncol Biol Phys
(2013) - et al.
Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma: Results of first 85 patients
J Gastrointest Surg
(2010) - et al.
Stereotactic body radiation therapy for nonresectable tumors of the pancreas
J Surg Res
(2012) - et al.
Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma
Radiother Oncol
(2005) - et al.
Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer
Int J Radiat Oncol Biol Phys
(2011)
Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity
Int J Radiat Oncol Biol Phys
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-01 FFCD/SFRO study
Ann Oncol
Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma
Radiother Oncol
Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis
Dig Liver Dis
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma
Pancreatology
Cancer statistics, 2013
CA Cancer J Clin
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
BMJ
Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy
Phys Med Biol
Meta-analysis of summary survival curve data
Stat Med
The combination of estimates from different experiments
Biometrics
Quantifying heterogeneity in a meta-analysis
Stat Med
Operating characteristics of a rank correlation test for publication bias
Biometrics
Bias in meta-analysis detected by a simple, graphical test
BMJ
Cited by (0)
Conflict of interest: none.